Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
4.180
-0.050 (-1.18%)
At close: Mar 6, 2026, 4:00 PM EST
4.180
0.00 (0.00%)
After-hours: Mar 6, 2026, 4:04 PM EST
Lisata Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 1.07 | 1 | - | - | - | - | |
| Gross Profit | 1.07 | 1 | - | - | - | - | |
| Selling, General & Admin | 11.38 | 12.08 | 12.97 | 14.14 | 11.47 | 9.89 | |
| Research & Development | 9.77 | 11.33 | 12.73 | 13.07 | 17.58 | 9.25 | |
| Operating Expenses | 21.15 | 23.41 | 25.71 | 27.21 | 29.05 | 19.15 | |
| Operating Income | -20.08 | -22.41 | -25.71 | -27.21 | -29.05 | -19.15 | |
| Interest & Investment Income | 1.02 | 1.88 | 2.72 | 1.05 | 0.15 | 0.13 | |
| Other Non Operating Income (Expenses) | -0.04 | -0.16 | -0.09 | -0.06 | -0.08 | - | |
| EBT Excluding Unusual Items | -19.1 | -20.68 | -23.07 | -26.21 | -28.97 | -19.01 | |
| Gain (Loss) on Sale of Assets | -0.1 | -0.1 | -0.1 | -0.1 | - | - | |
| Pretax Income | -19.2 | -20.78 | -23.17 | -56.7 | -28.97 | -19.01 | |
| Income Tax Expense | -0.96 | -0.8 | -2.33 | -2.48 | -1.51 | -10.87 | |
| Earnings From Continuing Operations | -18.24 | -19.99 | -20.84 | -54.23 | -27.47 | -8.14 | |
| Net Income to Company | -18.24 | -19.99 | -20.84 | -54.23 | -27.47 | -8.14 | |
| Minority Interest in Earnings | - | - | - | - | - | -0.01 | |
| Net Income | -18.24 | -19.99 | -20.84 | -54.23 | -27.47 | -8.15 | |
| Net Income to Common | -18.24 | -19.99 | -20.84 | -54.23 | -27.47 | -8.15 | |
| Shares Outstanding (Basic) | 9 | 8 | 8 | 5 | 4 | 1 | |
| Shares Outstanding (Diluted) | 9 | 8 | 8 | 5 | 4 | 1 | |
| Shares Change (YoY) | 3.87% | 3.17% | 55.85% | 40.46% | 258.29% | 49.54% | |
| EPS (Basic) | -2.12 | -2.40 | -2.58 | -10.47 | -7.45 | -7.92 | |
| EPS (Diluted) | -2.12 | -2.40 | -2.58 | -10.47 | -7.45 | -7.92 | |
| Free Cash Flow | -17.26 | -19.36 | -20.03 | -21.46 | -22.31 | -8.84 | |
| Free Cash Flow Per Share | -2.01 | -2.32 | -2.48 | -4.14 | -6.05 | -8.59 | |
| Gross Margin | 100.00% | 100.00% | - | - | - | - | |
| Operating Margin | -1876.54% | -2240.90% | - | - | - | - | |
| Profit Margin | -1704.86% | -1998.50% | - | - | - | - | |
| Free Cash Flow Margin | -1612.71% | -1935.60% | - | - | - | - | |
| EBITDA | -19.91 | -22.24 | -25.52 | -27.14 | -29 | -19.08 | |
| D&A For EBITDA | 0.17 | 0.17 | 0.19 | 0.07 | 0.06 | 0.06 | |
| EBIT | -20.08 | -22.41 | -25.71 | -27.21 | -29.05 | -19.15 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.